Search hospitals > Pennsylvania > West Chester

Chester County Hospital

Claim this profile
West Chester, Pennsylvania 19380
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
Conducts research for Fallopian Tube Cancer
95 reported clinical trials
3 medical researchers
Photo of Chester County Hospital in West ChesterPhoto of Chester County Hospital in West Chester

Summary

Chester County Hospital is a medical facility located in West Chester, Pennsylvania. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Fallopian Tube Cancer and other specialties. Chester County Hospital is involved with conducting 95 clinical trials across 156 conditions. There are 3 research doctors associated with this hospital, such as William E. Luginbuhl, Maureen Hewitt, MD, and Andre A. Konski.

Area of expertise

1Breast Cancer
Global Leader
Chester County Hospital has run 28 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
PR positive
2Lung Cancer
Global Leader
Chester County Hospital has run 18 trials for Lung Cancer. Some of their research focus areas include:
Stage I
Stage II
EGFR positive

Top PIs

Clinical Trials running at Chester County Hospital

Ovarian Cancer
Lung Cancer
Uterine Cancer
Prostate Cancer
Breast Cancer
Endometrial Adenocarcinoma
ALK Gene Rearrangement
Prostate Adenocarcinoma
Colon Cancer
Neonatal Sepsis
Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Chester County Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security